Skip to main content
SpringerLink
Log in

Early Repolarization Syndrome and Implantable Cardioverter–Defibrillators

  • Chapter
  • First Online:
Book cover Early Repolarization Syndrome

  • 523 Accesses

Abstract

The role of an implantable cardioverter–defibrillator (ICD) in patients with ERS still needs to be considered, since there have been no prospective, randomized studies that have examined the effect of ICDs compared with antiarrhythmic drugs in patients with ERS and ventricular fibrillation (VF). However, theoretically, ICDs must be the first-line strategy for patients with ERS because ICDs are effective in patients with a high risk of sudden cardiac death, regardless of underlying heart disease. An essential problem of ICDs is that they cannot prevent the occurrence of tachycardia attacks, and this limits their clinical usefulness. Especially during an electrical storm, it induces multiple shocks to terminate VF and may deteriorate the patients’ outcome. Another unresolved problem of ICDs is inappropriate therapy which demonstrated a 10–20% incidence in the previous large clinical trials. To program relatively high tachycardia detection rate and long detection rate are possible strategy to reduce risks of inappropriate and unnecessary ICD shocks. Another attractive capability of ICD is that it stores electrograms during the episode of VF. Analyzing the mode of onset or electrocardiographic manifestations at the episodes of ventricular arrhythmia is an effective strategy to clarify the underlying mechanism of ER and VF.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576–83.

    Article  Google Scholar 

  2. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone.[comment]. Circulation. 2000;101(11):1297–302.

    Article  CAS  PubMed  Google Scholar 

  3. Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102(7):748–54.

    Article  CAS  PubMed  Google Scholar 

  4. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. Eur Heart J. 2000;21:2071–8.

    Article  CAS  PubMed  Google Scholar 

  5. Domanski MJ, Sakseena S, Epstein AE, et al. Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias. AVID Investigators. Antiarrhythmics Versus Implantable Defibrillators. J Am Coll Cardiol. 1999;34:1090–5.

    Article  CAS  PubMed  Google Scholar 

  6. Sheldon R, Connolly S, Krahn A, et al. Identification of patients most likely to benefit from implantable cardioverter-defibrillator therapy: the Canadian Implantable Defibrillator Study. Circulation. 2000;101:1660–4.

    Article  CAS  PubMed  Google Scholar 

  7. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 1996;335:1933–40.

    Article  CAS  PubMed  Google Scholar 

  8. Bardy GH, Lee KL, Mark DB, et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter- defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225–37.

    Article  CAS  PubMed  Google Scholar 

  9. Haïssaguerre M, Derval N, Sacher F, et al. Sudden cardiac arrest associated with early repolarization. N Engl J Med. 2008;358:2016–23.

    Article  PubMed  Google Scholar 

  10. Aizawa Y, Chinushi M, Hasegawa K, et al. Electrical storm in idiopathic ventricular fibrillation is associated with early repolarization. J Am Coll Cardiol. 2013;62(11):1015–9. doi:10.1016/j.jacc.2013.05.030.

    Article  PubMed  Google Scholar 

  11. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol. 1992;20:1391–6.

    Article  CAS  PubMed  Google Scholar 

  12. Kamakura S, Ohe T, Nakazawa K, et al. Long-term prognosis of probands with Brugada-pattern ST-elevation in leads V1-V3. Circ Arrhythm Electrophysiol. 2009;2:495–503.

    Article  PubMed  Google Scholar 

  13. Brugada R, Brugada J, Antzelevitch C, et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation. 2000;101:510–5.

    Article  CAS  PubMed  Google Scholar 

  14. Priori SG, Napolitano C, Gasparini M, et al. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation. 2002;105:1342–7.

    Article  PubMed  Google Scholar 

  15. Belhassen B, Shapir I, Shoshani D, et al. Idiopathic ventricular fibrillation: inducibility and beneficial effects of class I antiarrhythmic agents. Circulation. 1987;75(4):809–16.

    Article  CAS  PubMed  Google Scholar 

  16. Meissner MD, Lehmann MH, Steinman RT, et al. Ventricular fibrillation in patients without significant structural heart disease: a multicenter experience with implantable cardioverter-defibrillator therapy. J Am Coll Cardiol. 1993;21(6):1406–12. doi:10.1016/0735-1097(93)90317-T.

    Article  CAS  PubMed  Google Scholar 

  17. Exner DV, Pinski SL, Wyse DG, et al. Electrical storm presages nonsudden death: the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial. Circulation. 2001;103:2066–71.

    Article  CAS  PubMed  Google Scholar 

  18. Kadish A, Dyer A, Daubert JP, for the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350(21):2151–8.

    Article  CAS  PubMed  Google Scholar 

  19. Daubert JP, Zareba W, Cannom DS, et al. for the MADIT II Investigators. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol. 2008;51(14):1357–65.

    Article  PubMed  Google Scholar 

  20. Poole JE, Johnson GW, Hellkamp AS, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med. 2008;359(10):1009–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Mitka M. New study supports lifesaving benefits of implantable defibrillation devices. JAMA. 2009;302(2):134–5.

    Article  CAS  PubMed  Google Scholar 

  22. Auricchio A, Schloss EJ, Kurita T, et al. Low inappropriate shock rates in patients with single- and dual/triple-chamber implantable cardioverter-defibrillators using a novel suite of detection algorithms: PainFree SST trial primary results. Heart Rhythm. 2015;12(5):926–36.

    Article  PubMed  Google Scholar 

  23. Wilkoff BL, Ousdigian KT, Sterns LD, et al. A comparison of empiric to physician-tailored programming of implantable cardioverter-defibrillators: results from the prospective randomized multicenter EMPIRIC trial. J Am Coll Cardiol. 2006;48:330–9.

    Article  PubMed  Google Scholar 

  24. Wilkoff BL, Williamson BD, Stern RS, et al. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. J Am Coll Cardiol. 2008;52:541–50.

    Article  PubMed  Google Scholar 

  25. Moss AJ, Schuger C, Beck CA, et al. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med. 2012;367:2275–83.

    Article  CAS  PubMed  Google Scholar 

  26. Sears SF, Conti JB. Understanding implantable cardioverter defibrillator shocks and storms: medical and psychosocial considerations for research and clinical care. Clin Cardiol. 2003;26:107–11.

    Article  PubMed  Google Scholar 

  27. Schron EB, Exner DV, Yao Q, et al. Quality of life in the antiarrhythmics versus implantable defibrillators trial. Impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation. 2002;105:589–94.

    Article  PubMed  Google Scholar 

  28. Borne RT, Varosy PD, Masoudi FA. Implantable cardioverter-defibrillator shocks. epidemiology, outcomes, and therapeutic approaches. JAMA Intern Med. 2013;173(10):859–65.

    Article  PubMed  Google Scholar 

  29. Deisenhofer I, Kolb C, Ndrepepa G, et al. Do current dual chamber cardioverter defibrillators have advantages over conventional single chamber cardioverter defibrillators in reducing inappropriate therapies? A randomized, prospective study. J Cardiovasc Electrophysiol. 2001;12:134–42.

    Article  CAS  PubMed  Google Scholar 

  30. Kolb C, Sturmer M, Sick P, et al. Reduced risk for inappropriate implantable cardioverter-defibrillator shocks with dual-chamber therapy compared with single-chamber therapy: results of the randomized OPTION study. JACC Heart Fail. 2014;2(6):611–9.

    Article  PubMed  Google Scholar 

  31. Noda T, Kurita T, Nitta T, et al. Appropriate duration of driving restrictions after inappropriate therapy from implantable cardiac shock devices-interim analysis of the Nippon Storm Study. Circ J. 2014;78(8):1989–91.

    Article  PubMed  Google Scholar 

  32. Maisel WH, Moynahan M, Zuckerman BD, et al. Pacemaker and ICD generator malfunctions: analysis of Food and Drug Administration annual reports. JAMA. 2006;295:1901.

    Article  CAS  PubMed  Google Scholar 

  33. Maisel WH. Pacemaker and ICD generator reliability: meta-analysis of device registries. JAMA. 2006;295:1929.

    Article  CAS  PubMed  Google Scholar 

  34. Greenspon AJ, Patel JD, Lau E, et al. 16-year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States 1993 to 2008. J Am Coll Cardiol. 2011;58(10):1001–6. doi:10.1016/j.jacc.2011.04.03.

    Article  PubMed  Google Scholar 

  35. Burke MC, Gold MR, Knight BP, et al. Safety and efficacy of the totally subcutaneous implantable defibrillator. 2-year results from a pooled analysis of the IDE Study and EFFORTLESS Registry. J Am Coll Cardiol. 2015;65:1605–165.

    Article  PubMed  Google Scholar 

  36. Chung MK, Szymkiewicz SJ, Shao M, et al. Aggregate national experience with the wearable cardioverter-defibrillator: event rates, compliance, and survival. J Am Coll Cardiol. 2010;56:194–203.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Kutyifa V, Moss AJ, Klein H, et al. Use of the wearable cardioverter defibrillator in high-risk cardiac patients: data from the prospective registry of patients using the Wearable Cardioverter Defibrillator (WEARIT-II Registry). Circulation. 2015;132:1613–9.

    Article  PubMed  Google Scholar 

  38. Sasaki S, Tomita H, Shibutani S, et al. Usefulness of the wearable cardioverter-defibrillator in patients at high risk for sudden cardiac death: a single-center primary experience. Circ J. 2014;78(12):2987–9.

    Article  PubMed  Google Scholar 

  39. Matsuo K, Kurita T, Inagaki M, et al. The circadian pattern of the development of ventricular fibrillation in patients with Brugada syndrome. Eur Heart J. 1999;20:465–70.

    Article  CAS  PubMed  Google Scholar 

  40. Kakishita M, Kurita T, Matsuo K, et al. Mode of onset of ventricular fibrillation in patients with Brugada syndrome detected by implantable cardioverter defibrillator Therapy. J Am Coll Cardiol. 2000;36:1646–53.

    Article  CAS  PubMed  Google Scholar 

  41. Aizawa Y, Tamura M, Chinushi M, et al. Idiopathic ventricular fibrillation and bradycardia-dependent intraventricular block. Am Heart J. 1993;126:1473–4.

    Article  CAS  PubMed  Google Scholar 

  42. Aizawa Y, Sato M, Ohno S, et al. Circadian pattern of fibrillatory events in non-Brugada-type idiopathic ventricular fibrillation with a focus on J waves. Heart Rhythm. 2014;11(12):2261–6.

    Article  PubMed  Google Scholar 

  43. Nam BG, Ko KH, Jun K, et al. Mode of onset of ventricular fibrillation in patients with early repolarization pattern vs. Brugada syndrome. Eur Heart J. 2010;31:330–9.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiovascular Center, Department of Internal Medicine, School of Medicine, Kindai University, Higashiosaka, Osaka, Japan

    Takashi Kurita M.D.

Authors
  1. Takashi Kurita M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takashi Kurita M.D. .

Editor information

Editors and Affiliations

  1. Department of Cardiovascular Medicine, Nippon Medical School, Tokyo, Japan

    Wataru Shimizu

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Singapore Pte Ltd.

About this chapter

Cite this chapter

Kurita, T. (2018). Early Repolarization Syndrome and Implantable Cardioverter–Defibrillators. In: Shimizu, W. (eds) Early Repolarization Syndrome. Springer, Singapore. https://doi.org/10.1007/978-981-10-3379-7_8

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-3379-7_8

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-3378-0

  • Online ISBN: 978-981-10-3379-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation